Catalyzing Pediatric Tuberculosis Innovations (CaP TB)

Overview

This brief provides a summary of the evidence that supports use of shorter regimens for preventive TB treatment (3RH and 3HP). It provides the most updated information on the availability of  formulations for HP regimen (including for pediatric populations), as well as the latest information on costs. It also provides practical guidance on the roll-out of the 2 regimens, considering short term, as well as long/medium term strategies.